You are viewing the site in preview mode

Skip to main content

Table 2 Summary of Genz-644282 and The-0504 efficacy in tumor-bearing mice models of human cell lines of different origin

From: High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors

Tumor model TGI (%) RESPONSE at 1.9 mg/Kg
ORR (%)
Genz-644282 The-0504 Genz-644282a The-0504
Pancreatic (PaCa44) 64.2 100 33.3% SD 100% MCR
16.7 100 66.7% PD
Colorectal (HT29) Not available Not available 33.3% SD 66.7% CR
16.6 100 66.7% PD 33.3% PR
Breast (MDA-MB 231) 70.1 100 16.7% SD 83.3% MCR
0 100 83.3% PD 16.7% CR
Liver (HepG2) 55.5 100 25.0% PR 100% MCR
25.0 100 75.0% PD
Pancreatic (PDX)a 0 93.6 100% PD 33.3% MCR
0 83.3 16.7% CR,
33.3% PR,
16.7% SD
  1. a Nab-paclitaxel at 10 mg/Kg instead of Genz-644282 was used in PDX model
  2. TGI Tumor Growth Inhibition, ORR Objective Response Rate, MCR Maintained Complete Response, CR Complete Response, PR Partial Response, SD Stable Disease, PD Progressive Disease
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us